The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined Nucala (mepolizumab), from UK pharma major GlaxoSmithKline (LSE: GSK), in an early benefit assessment as to whether the drug offers an added benefit for patients in comparison with the appropriate comparator therapy.
Nucala has been approved in Europe and the USA since the end of 2015 for the treatment of adults with severe refractory eosinophilic asthma.
According to the findings, the specifications of the appropriate comparator therapy were not implemented in the two studies of direct comparisons cited by the drug manufacturer; and the indirect comparison conducted by the manufacturer was unsuitable for the benefit assessment. IQWiG therefore sees no hint of an added benefit of mepolizumab in comparison with the appropriate comparator therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze